Back to top
more

Glaukos (GKOS)

(Real Time Quote from BATS)

$130.00 USD

130.00
5,593

-0.98 (-0.75%)

Updated Oct 7, 2024 10:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Medtronic Poised on Strong Fundamentals Despite Several Woes

On Feb 23, we issued an updated research report on medical device major, Medtronic plc (MDT).

    Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise

    On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).

      Patterson Companies (PDCO) Earnings Beat Estimates in Q3

      Patterson Companies Inc. (PDCO) reported third-quarter fiscal 2017 adjusted earnings of 58 cents per share from continuing operations, which came higher than the Zacks Consensus Estimate of 57 cents.

        Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat

        Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.

          Inovalon (INOV) Q4 Earnings In Line, Revenue Beat Estimates

          Inovalon Holdings, Inc. (INOV) reported fourth-quarter 2016 adjusted earnings of 2 cents per share, which came in line with the Zacks Consensus Estimate.

            Align Expands Internationally with Dental Couture Buyout

            Align Technology (ALGN) has recently announced the acquisition of Dubai, UAE and Nicosia, Cyprus-based distributor, G.L. Dental Couture Limited.

              Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter

              Teleflex Incorporated (TFX) recently announced 510(k) clearance for its TrapLiner Catheter from the US FDA for a full fledged commercial launch in the country.

                Henry Schein Inks Agreement for Rijuven's CardioSleeve

                Henry Schein, Inc. (HSIC) recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. to sell the latter's CardioSleeve device

                  Wright Medical (WMGI) Posts Narrower-than-Expected Q4 Loss

                  Wright Medical Group N.V. (WMGI) reported adjusted loss of 6 cents per share in the fourth quarter of 2016, narrower than loss of 8 cents reported in the year-ago quarter and the Zacks Consensus Estimate of a loss of 11 cents.

                    DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles

                    DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.

                      Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View

                      Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.

                        Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4

                        Ecolab Inc. (ECL) reported fourth-quarter 2016 adjusted earnings of $1.25 per share, which missed the Zacks Consensus Estimate of $1.27.

                          Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View

                          Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.

                            Henry Schein to Acquire SAS to Strengthen Dental Offerings

                            Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).

                              DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues

                              DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents.

                                Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial

                                Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial

                                  Allscripts (MDRX) Q4 Earnings Miss Estimates, View Upbeat

                                  Allscripts Healthcare Solutions, Inc.(MDRX) reported fourth-quarter 2016 earnings of 10 cents per share, which missed the Zacks Consensus Estimate by 2 cents.

                                    DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4

                                    DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.

                                      GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y

                                      GNC Holdings Inc. (GNC) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 37 cents, down 88.1% and also missed the Zacks Consensus Estimate by 81.1%.

                                        Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT

                                        Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.

                                          LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View

                                          Laboratory Corporation of America Holdings (LH) or LabCorp reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.15, up 8.6% from the year-ago quarter.

                                            Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View

                                            Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.

                                              Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss

                                              Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.

                                                Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter

                                                Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.

                                                  CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4

                                                  CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.